Search
Iotrolan
go.drugbank.com/drugs/DB09487ApprovedWithdrawnNonionic, isotonic contrast medium designed for intrathecal use.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsNaxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making
Bromelains
go.drugbank.com/drugs/DB13281ApprovedInvestigationalBromelain is a protease enzyme derived from the stems of pineapples that is composed of a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase … Bromelain holds potential therapeutic effect as a treatment of conditions including angina pectoris, bronchitis, sinusitis, surgical trauma, and osteoarthritis.
Categories: Preparations for Treatment of Wounds and UlcersProducts: Bromelain Pineapple Enzyme 50 Mg Nu LifeEzogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnEzogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. … FDA approved in June 10, 2011 under the name of ezogabine.
Kanamycin
go.drugbank.com/drugs/DB01172ApprovedInvestigationalVet approvedWithdrawnKanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.
Synonyms: Kanamycin A, 4,6-diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-α-D-glucosideCategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalA Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexZiftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.
Synonyms: (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile, (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1Hindole-2-carbonitrileVadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigationalThese transcription factors serve a multitude of roles, including the stimulation of erythropoiesis. … [A244165] Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile non-inferior to [darbepoetin alfa] for the treatment of anemia in patients with CKD undergoing dialysis
Procarbazine
go.drugbank.com/drugs/DB01168ApprovedInvestigationalAn antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeVaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).